Elevance Health vs Humana

ELV trades at a P/E ratio of 17.55, which is substantially lower than HUM's P/E of 38.17, indicating a more attractive valuation for ELV on a price-to-earnings basis. ELV's market capitalization stands at $90.33 billion, considerably larger than HUM's $48.12 billion. Despite its larger size, ELV's revenue growth of 1.4% is modest compared to HUM's robust 26.2% growth. However, ELV's lower P/E ratio suggests that investors are paying less for each dollar of ELV's earnings compared to HUM, making ELV appear undervalued relative to its earnings power. While HUM's high revenue growth is a positive indicator for future potential, its current valuation appears stretched when considering its profitability. ELV, on the other hand, offers a more balanced profile with a reasonable valuation supported by stronger profitability metrics. The significant difference in P/E ratios suggests that ELV presents a better value proposition for investors prioritizing earnings multiples.

This indicates that ELV is much more effective at converting revenue into profit. Furthermore, ELV's return on equity (ROE) stands at 11.13%, substantially higher than HUM's 6.89%, signifying better efficiency in generating profits from shareholder investments. ELV also shows a slightly better return on assets (ROA) at 3.83% compared to HUM's 3.9%, though this metric is closer between the two. The stark difference in net profit margin and ROE clearly positions ELV as the more profitable and financially efficient company.

ELV is exhibiting strong upward momentum, with its RSI at 60.43 and trading above its 50-day ($397.22) and 200-day ($361.05) moving averages. Its MACD value of 4.59 suggests positive momentum, and its Stochastic reading of 74.25 indicates it is approaching overbought territory but still has room to run within a strong trend. ELV's price is trading near its 52-week high of $436.24, currently at $417.23. HUM also shows positive technicals, with an RSI of 71.85 indicating it is in overbought territory, and its MACD at 6.01 suggests strong upward momentum. It is trading above its 50-day ($388.96) and 200-day ($283.21) moving averages. HUM's price is also near its 52-week high of $428.88, currently at $405.97. While both stocks show bullish technicals, ELV's RSI is less extended, suggesting potentially more room for upside before a pullback, and its price action is more consistently above key moving averages.

Analyst sentiment strongly favors ELV, with 22 analysts issuing a median target price of $457, representing a significant upside from its current price. The ratings are overwhelmingly positive: 3 Strong Buys, 12 Buys, and only 7 Holds, with no Sell ratings. This indicates a high degree of confidence from the analyst community in ELV's future performance. HUM also garners positive analyst attention, with a median target price of $415, suggesting modest upside. However, the ratings are more mixed: 1 Strong Buy, 11 Buys, 13 Holds, and 1 Sell. This distribution suggests a less uniform conviction among analysts compared to ELV, with a notable number of Hold ratings.

For ELV, key risks include its relatively modest revenue growth of 1.4%, which could slow further if market conditions deteriorate or competition intensifies. While its profitability is strong, maintaining these margins in a challenging economic environment could prove difficult. A significant shift in healthcare policy or regulatory changes could also impact its business model. HUM faces higher risks due to its significantly lower net profit margin and less consistent earnings performance, despite its impressive revenue growth. Its higher P/E ratio makes it more vulnerable to a valuation reset if growth expectations are not met. Furthermore, its reliance on continued high revenue growth to justify its valuation presents a substantial risk if that growth falters. The presence of a Sell rating from one analyst also highlights potential concerns.